Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer

Strahlentherapie und Onkologie

Volumn 183, Issue 9, 2007, Pages 490-496

  Yoshioka, Yasuo ^a   Inoue, Takehiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinically localized; Prostate cancer; Prostate Risk Index (PRIX); Radiotherapy; Risk classification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CLASSIFICATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MALE; NOMOGRAM; PATIENT SELECTION; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PROSTATE RISK INDEX; SCORING SYSTEM;

HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 34548295260     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1692-3     Document Type: Article

References (20)

1. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-21.
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
3. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-41.
4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
5. Galalae RM, Martinez A, Nuernberg N, et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 2006;182:135-41.
6. Goldner G, Wachter S, Wachter-Gerstner N, et al. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 2006;182:537-42.
7. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352-9.
8. Kovacs G, Potter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 2005;74:137-48.
9. Mock U, Bogner J, Georg D, et al. Comparative treatment planning on localized prostate carcinoma. Conformal photon- versus proton-based radiotherapy. Strahlenther Onkol 2005;181:448-55.
10. National Comprehensive Cancer Network. Prostate cancer - version 2.2005. NCCN Clinical Practice Guidelines in Oncology. Jenkintown, PA, USA: NCCN, 2005 (http://www.nccn.org/index.html).
11. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
12. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
13. Partin AW, Yoo J, Carter HB, et al. The use of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
14. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
15. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
16. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-11.
17. Roach M III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 94 13. J Clin Oncol 2003;21:1904-11.
18. Roach M III, Marquez C, Hae-Sook Y, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate-specific antigen and Gleason Score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7.
19. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-52.
20. Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006;80:62-8.